港股市场个股详情

09969 诺诚健华

添加自选

5.080
-0.040-0.78%

未开盘 05/07 16:08 (北京)

89.54亿总市值-12860市盈率TTM

诺诚健华股票讨论区

登录发表评论

诺诚健华

03/18 09:57

专栏InnoCare to Host 2023 Earnings Call on March 28, 2024

$诺诚健华(09969.HK)$； $诺诚健华-U(688428.SH)$

诺诚健华

03/13 08:32

专栏InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China

InnoCare Pharma ( $诺诚健华(09969.HK)$； $诺诚健华-U(688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor...

诺诚健华

03/11 08:39

专栏Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD

InnoCare Pharma ( $诺诚健华(09969.HK)$; $诺诚健华-U(688428.SH)$), a commercial-stage biotech company, announced today that the latest data of the novel TYK2 inhibitor ICP-332 developed by the Company for the treatment of patients with moderate-to-severe atopic dermatitis (AD) has been released at the 2024 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral ...

Moomoo AI

02/15 08:21

InnoCare Pharma's balance sheet indicates it can handle adversity with more cash than debt. Despite an EBIT loss last year, solid revenue growth may suggest a path to profitability.

Does InnoCare Pharma (HKG:9969) Have A Healthy Balance Sheet?

诺诚健华

01/24 08:42

专栏InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma ( $诺诚健华(09969.HK)$； $诺诚健华-U(688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center. This is the first time that zurletrec...

诺诚健华

01/22 09:44

专栏InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program

InnoCare ( $诺诚健华(09969.HK)$； $诺诚健华-U(688428.SH)$) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been recently approved by the Medical Products Administration of Guangdong Province, under the early access program in Guangdong-Hong Kong-Macao Greater Bay Area (“Gre...

诺诚健华

01/16 11:13

专栏InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

InnoCare Pharma ( $诺诚健华(09969.HK)$; $诺诚健华-U(688428.SH)$), a commercial-stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company's B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. This is InnoCare’s fifth innovative drug to enter the clinical stage in the U.S.
This is a Phase I study to evaluate the...

诺诚健华

2023/12/28 08:50

专栏InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference

InnoCare Pharma ( $诺诚健华(09969.HK)$ $诺诚健华-U(688428.SH)$) announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S. Pacific Standard Time (00:30 AM, January 11, 2023, Beijing Time), to update the Company’s latest development.
The J.P. Morgan Healthcare Conference is the most influential event for the...

诺诚健华

2023/12/18 08:50

专栏InnoCare Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer (CFO). He reports to the Co-founder, Chairwoman and CEO of InnoCare Pharma, Dr. Jasmine Cui. Mr. Fu is responsible for the Company’s growth strategy, financial management, investment & financin...

诺诚健华

2023/12/17 16:15

专栏InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis (AD).
ICP-332 in AD patients treated for 4 weeks...

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

港股

综合热度